Clinical advances in biological therapy for generalized pustular psoriasis: a review

References

• Blair HA. Spesolimab: first approval. Drugs. 2022;82:1681. doi: 10.1007/S40265-022-01801-4
   PubMedGoogle Scholar
• Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402:1541–1551. doi: 10.1016/s0140-6736(23)01378-8
   Web of Science ®Google Scholar
• Yang SF, Lin MH, Chou PC, et al. Genetics of generalized pustular psoriasis: current understanding and implications for future therapeutics. Genes (Basel). 2023;14:1297. doi: 10.3390/genes14061297
   PubMed Web of Science ®Google Scholar
• Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45:1371–1380. doi: 10.1111/1346-8138.14664
   PubMed Web of Science ®Google Scholar
• Du Y, Yan Q, Chen M, et al. Efficacy of Adalimumab in pediatric generalized pustular psoriasis: case series and literature review. J Dermatolog Treat. 2022;33:2862–2868. doi: 10.1080/09546634.2022.2089327
   PubMed Web of Science ®Google Scholar
• Fukushima H, Iwata Y, Arima M, et al. Efficacy and safety of treatment with anti-tumor necrosis factor-α drugs for severe impetigo herpetiformis. J Dermatol. 2021;48:207–210. doi: 10.1111/1346-8138.15635
   PubMed Web of Science ®Google Scholar
• Yamashita T, Hamada T, Maruta Y, et al. An effective and promising treatment with Adalimumab for impetigo herpetiformis with postpartum flare-up. Int J Dermatol. 2019;58:350–353. doi: 10.1111/IJD.14141
   PubMed Web of Science ®Google Scholar
• Hay RAS, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to Adalimumab therapy. Clin Exp Dermatol. 2014;39:751–752. doi: 10.1111/ced.12392
   PubMed Web of Science ®Google Scholar
• Kawakami H, Maeda T, Abe N, et al. Efficacy of Adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol. 2015;42:94–95. doi: 10.1111/1346-8138.12704
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Komine M, Karakawa M, et al. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017;44:202–204. doi: 10.1111/1346-8138.13632
   PubMed Web of Science ®Google Scholar
• Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents. Pediatr Rheumatol Online J. 2019;17:37. doi: 10.1186/s12969-019-0338-1
   PubMed Web of Science ®Google Scholar
• Kamal K, Gj R, Hijaz B, et al. Generalized pustular psoriasis-like widespread eruption following COVID-19 infection in a patient with spondyloarthropathy on Adalimumab. Exp Dermatol. 2024;33:e14889. doi: 10.1111/exd.14889
   PubMed Web of Science ®Google Scholar
• Kucharekova M, Winnepenninckx V, Frank J, et al. Generalized pustulosis induced by Adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. Int J Dermatol. 2008;47:25–28. doi: 10.1111/j.1365-4632.2008.03954.x
   PubMed Web of Science ®Google Scholar
• Kimura U, Kinoshita A, Haruna K, et al. Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis. J Dermatol. 2012;39:286–287. doi: 10.1111/j.1346-8138.2011.01344.x
   PubMed Web of Science ®Google Scholar
• Yang X, Wang J, Wang H, et al. Acute generalized pustular psoriasis developed resistance to adalimumab was successfully treated with narrowband ultraviolet B and acitretin: a case report. Clin Cosmet Investig Dermatol. 2022;15:2541–2546. doi: 10.2147/CCID.S391463
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Mizutani YH, Matsuyama K, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol. J Dermatol. 2020;47:e262–e263. doi: 10.1111/1346-8138.15355
   PubMed Web of Science ®Google Scholar
• Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228–233. doi: 10.1136/ANNRHEUMDIS-2017-212196
   PubMed Web of Science ®Google Scholar
• Yatsuzuka K, Matsumoto T, Sakane Y, et al. The use of certolizumab pegol to successfully treat generalized pustular psoriasis combined with psoriatic uveitis. J Dermatol. 2023;50:e175–e176. doi: 10.1111/1346-8138.16704
   PubMed Web of Science ®Google Scholar
• Okubo Y, Umezawa Y, Sakurai S, et al. Efficacy and safety of certolizumab pegol in japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 52-week results. Dermatol Ther. 2022;12:1397–1415. doi: 10.1007/s13555-022-00741-x
   PubMed Web of Science ®Google Scholar
• Koizumi H, Tokuriki A, Oyama N, et al. Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis. J Dermatol. 2017;44:723–724. doi: 10.1111/1346-8138.13530
   PubMed Web of Science ®Google Scholar
• Esposito M, Mazzotta A, Casciello C, et al. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. 2008:216:355–360. doi: 10.1159/000117706
   PubMed Web of Science ®Google Scholar
• Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-α therapy in childhood pustular psoriasis. Dermatology. 2006;213:350–352. doi: 10.1159/000096202
   PubMed Web of Science ®Google Scholar
• Georgesen C, Wildman H, Wang X, et al. Pediatric pustular psoriasis responsive to cyclosporine bridged to etanercept: a treatment approach. Dermatol Online J. 2017;23:13030/qt9787b6c0. doi: 10.5070/d32311037267
   PubMedGoogle Scholar
• Fialová J, Vojáčková N, Vaňousová D, et al. Juvenile generalized pustular psoriasis treated with etanercept. Dermatol Ther. 2014;27:105–108. doi: 10.1111/dth.12065
   PubMed Web of Science ®Google Scholar
• Lin YC, Jeng YC, Aala WJF, et al. Transcriptomic responses of peripheral blood mononuclear cells to cyclosporin and etanercept in a female infant with juvenile generalized pustular psoriasis. Exp Dermatol. 2023;32:1299–1305. doi: 10.1111/exd.14835
   PubMed Web of Science ®Google Scholar
• Cuperus E, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin. JAAD Case Rep. 2018;4:192–195. doi: 10.1016/j.jdcr.2017.08.019
   PubMedGoogle Scholar
• Ephrem G, Jour G, Smith BL. Successful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection. J Med Liban. 2011;59:168–169.
   PubMedGoogle Scholar
• Brigant F, Clavel G, Chatelain D, et al. Letter: a case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J. 2011;17:11. doi: 10.5070/D38M24603S
   PubMedGoogle Scholar
• Torii H, Terui T, Matsukawa M, et al. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016;43:767–778. doi: 10.1111/1346-8138.13214
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38:321–334. doi: 10.1111/j.1346-8138.2010.00971.x
   PubMed Web of Science ®Google Scholar
• Torii H, Nakano M, Yano T, et al. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study. J Dermatol. 2017;44:552–559. doi: 10.1111/1346-8138.13698
   PubMed Web of Science ®Google Scholar
• Babuna Kobaner G, Polat Ekinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. Dermatol Ther. 2020;33:e13571. doi: 10.1111/dth.13571
   Web of Science ®Google Scholar
• Beksac B, Adisen E, Gurer MA. Treatment of generalized pustular psoriasis of pregnancy with infliximab. Cutis. 2021;107:E2–5. doi: 10.12788/cutis.0210
   PubMed Web of Science ®Google Scholar
• Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43:1439–1440. doi: 10.1111/1346-8138.13429
   PubMed Web of Science ®Google Scholar
• Sheth N, Greenblatt DT, Acland K, et al. Generalized pustular psoriasis of pregnancy treated with infliximab. Clin Exp Dermatol. 2009;34:521–522. doi: 10.1111/j.1365-2230.2008.02963.x
   PubMed Web of Science ®Google Scholar
• Tsang V, Dvorakova V, Enright F, et al. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e117–e119. doi: 10.1111/JDV.13388
   PubMed Web of Science ®Google Scholar
• Lu J, Li Y, Yu N, et al. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports. J Int Med Res. 2020;48:0300060520912091. doi: 10.1177/0300060520912091
   PubMed Web of Science ®Google Scholar
• Sugiura K, Endo K, Akasaka T, et al. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist. J Eur Acad Dermatol Venereol. 2015;29:2054–2056. doi: 10.1111/jdv.12590
   PubMed Web of Science ®Google Scholar
• Podlipnik S, de la Mora L, Alsina M, et al. Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL-36RN deficiency treated with infliximab: case report and review of the literature. Australas J Dermatol. 2017;58:e44–e47. doi: 10.1111/ajd.12489
   PubMed Web of Science ®Google Scholar
• Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab. Dermatol Ther. 2016;29:164–167. doi: 10.1111/dth.12325
   PubMed Web of Science ®Google Scholar
• Almutairi D, Sheasgreen C, Weizman A, et al. Generalized pustular psoriasis induced by infliximab in a patient with inflammatory bowel disease. J Cutan Med Surg. 2018;22:507–510. doi: 10.1177/1203475418758986
   PubMed Web of Science ®Google Scholar
• Zheng J, Gao Y, Ding Y. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis. Dermatol Ther. 2019;32:e13132. doi: 10.1111/dth.13132
   Web of Science ®Google Scholar
• Xia P, Li YH, Liu Z, et al. Recalcitrant paradoxical pustular psoriasis induced by infliximab: two case reports. World J Clin Cases. 2021;9:3655–3661. doi: 10.12998/wjcc.v9.i15.3655
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chiu YM, Chang Liao NF, et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study. J Am Acad Dermatol. 2021;85:337–344. doi: 10.1016/j.jaad.2019.12.001
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol. 2011;164:553–559. doi: 10.1111/j.1365-2133.2010.10137.x
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen Y, Yu Q, et al. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37:35–55. doi: 10.1007/S40259-022-00569-Z
   PubMed Web of Science ®Google Scholar
• Li L, Aviña-Zubieta JA, Bernstein CN, et al. Risk of multiple sclerosis among users of antitumor necrosis factor α in 4 canadian provinces: a population-based study. Neurology. 2023;100:E558–E567. doi: 10.1212/WNL.0000000000201472
   PubMedGoogle Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9:806. doi: 10.1093/ECCO-JCC/JJV096
   PubMed Web of Science ®Google Scholar
• Naik HB, Pichard DC, Schwartz DM, et al. Anakinra for refractory pustular psoriasis: a phase II, open-label, dose-escalation trial. J Am Acad Dermatol. 2022;87:1380–1383. doi: 10.1016/J.JAAD.2022.07.065
   PubMed Web of Science ®Google Scholar
• Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol. 2012;148:747–752. doi: 10.1001/archdermatol.2011.3208
   PubMedGoogle Scholar
• Mendonça LO, Grossi A, Caroli F, et al. A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of Interleukin-1 receptor antagonist (DIRA). Pediatr Rheumatol Online J. 2020;18:67. doi: 10.1186/s12969-020-00454-5
   PubMed Web of Science ®Google Scholar
• Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med. 2010;153:66–67. doi: 10.7326/0003-4819-153-1-201007060-00030
   PubMed Web of Science ®Google Scholar
• Hüffmeier U, Wätzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–204. doi: 10.1111/bjd.12548
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Piram M, Chiaverini C, et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics. 2013;132:e1043–e1047. doi: 10.1542/peds.2012-3935
   PubMed Web of Science ®Google Scholar
• Ulusoy E, Karaca NE, El-Shanti H, et al. Interleukin-1 receptor antagonist deficiency with a novel mutation; Late onset and successful treatment with canakinumab: a case report. J Med Case Rep. 2015;9:145. doi: 10.1186/s13256-015-0618-4
   PubMedGoogle Scholar
• Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition. Br J Dermatol. 2017;176:212–215. doi: 10.1111/bjd.14685
   PubMed Web of Science ®Google Scholar
• Gómez-García F, Sanz-Cabanillas JL, Viguera-Guerra I, et al. Scoping review on use of drugs targeting interleukin 1 pathway in DIRA and DITRA. Dermatol Ther. 2018;8:539–556. doi: 10.1007/S13555-018-0269-7
   Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab. Br J Dermatol. 2015;173:239–241. doi: 10.1111/bjd.13614
   PubMed Web of Science ®Google Scholar
• Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight. 2017;2:e94838. doi: 10.1172/JCI.INSIGHT.94838
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. Two cases of generalized pustular psoriasis successfully treated with bimekizumab. J Dermatol. 2023 Oct;50(10):e357–e358. doi: 10.1111/1346-8138.16866
   PubMed Web of Science ®Google Scholar
• Shukuin R, Koizumi H, Ebata A, et al. Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis. J Dermatol. 2023;50:e181–e182. doi: 10.1111/1346-8138.16707
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–751. doi: 10.1111/bjd.14702
   PubMed Web of Science ®Google Scholar
• Fujii A, Fujii K, Seishima M. Generalized pustular psoriasis with CARD14 variant c.526G>C (p.Asp176His) successfully treated with granulocyte and monocyte adsorption apheresis. Ther Apher Dial. 2019;23:298–299. doi: 10.1111/1744-9987.12816
   PubMed Web of Science ®Google Scholar
• Nakai Y, Ashida H, Kajita A, et al. Impetigo herpetiformis successfully treated with brodalumab. J Dermatol. 2022;49:e149–e150. doi: 10.1111/1346-8138.16285
   PubMed Web of Science ®Google Scholar
• Khemis A, Cavalié M, Montaudié H, et al. Rebound pustular psoriasis after brodalumab discontinuation. Br J Dermatol. 2016;175:1065–1066. doi: 10.1111/bjd.14627
   PubMed Web of Science ®Google Scholar
• Wang C, Torisu-Itakura H, Hanada T, et al. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study. J Dermato Treat. 2023;34:2229465. doi: 10.1080/09546634.2023.2229465
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29:1148–1155. doi: 10.1111/jdv.12773
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–362. doi: 10.1111/1346-8138.13622
   PubMed Web of Science ®Google Scholar
• Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33:325–332. doi: 10.1111/jdv.15287
   PubMed Web of Science ®Google Scholar
• Nagata M, Kamata M, Fukaya S, et al. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab. J Am Acad Dermatol. 2020;82:758–761. doi: 10.1016/J.JAAD.2019.09.040
   PubMed Web of Science ®Google Scholar
• Morita A, Okubo Y, Morisaki Y, et al. Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. Dermatol Ther. 2022;12:481–494. doi: 10.1007/s13555-021-00666-x
   PubMed Web of Science ®Google Scholar
• Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2022;36:e574–e576. doi: 10.1111/jdv.18069
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–1017. doi: 10.1111/1346-8138.13306
   PubMed Web of Science ®Google Scholar
• Reymundo A, Vilarrasa E, Baniandrés O, et al. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. J Eur Acad Dermatol Venereol. 2022;36:e849–e851. doi: 10.1111/jdv.18317
   PubMed Web of Science ®Google Scholar
• Dogra S, Bishnoi A, Narang T, et al. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2019;44:72–73. doi: 10.1111/ced.13731
   PubMed Web of Science ®Google Scholar
• Wu X, Yan T, Han C, et al. Rapid and sustained response of acute generalized pustular psoriasis of von Zumbusch to Secukinumab. J Eur Acad Dermatol Venereol. 2023;37:e338–e341. doi: 10.1111/jdv.18609
   PubMed Web of Science ®Google Scholar
• López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. J Dermatol. 2021;48:907–910. doi: 10.1111/1346-8138.15673
   PubMed Web of Science ®Google Scholar
• Jing G, Bin W, Ying ZZ. Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement. Pediatr Dermatol. 2021;38:1258–1263. doi: 10.1111/pde.14737
   PubMed Web of Science ®Google Scholar
• Zhu H, Song P, Du D, et al. Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy. Pediatr Dermatol. 2021;38:1366–1367. doi: 10.1111/pde.14795
   PubMed Web of Science ®Google Scholar
• Gabeff R, Safar R, Leducq S, et al. Successful therapy with secukinumab in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation. Int J Dermatol. 2019;58:e16–e17. doi: 10.1111/ijd.14293
   PubMed Web of Science ®Google Scholar
• Ho PH, Tsai TF. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work. J Dermatol. 2018;45:1353–1356. doi: 10.1111/1346-8138.14636
   PubMed Web of Science ®Google Scholar
• Ruan SF, Zhang LL, Liu Z, et al. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: A 48-week retrospective study. J Am Acad Dermatol. 2023;88:243–246. doi: 10.1016/J.JAAD.2022.04.064
   PubMed Web of Science ®Google Scholar
• Miao C, Chen Y, Wang Z, et al. Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis. J Dermatol. 2023;50:258–261. doi: 10.1111/1346-8138.16551
   PubMedGoogle Scholar
• Yoshikawa M, Rokunohe D, Kimura A, et al. Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases. J Dermatol. 2021;48:699–702. doi: 10.1111/1346-8138.15788
   PubMed Web of Science ®Google Scholar
• Neema S, Shrestha S, Sathu S, et al. Excellent response to secukinumab in treatment resistant impetigo herpetiformis. Indian Dermatol Online J. 2023;14:118–119. doi: 10.4103/idoj.idoj_115_22
   PubMedGoogle Scholar
• Kanatani Y, Shinkuma S, Matsumoto Y, et al. Recurrence of impetigo herpetiformis carrying compound heterozygous mutations in IL36RN after remission with secukinumab. J Dermatol. 2022;49:e108–e110. doi: 10.1111/1346-8138.16247
   PubMed Web of Science ®Google Scholar
• Zhang J, Xia P, Wan L, et al. Generalized pustular psoriasis of pregnancy successfully treated with secukinumab. Indian J Dermatol Venereol Leprol. 2023;89:886–888. doi: 10.25259/ijdvl_1060_2022
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hui RCY, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98:829–834 doi: 10.2340/00015555-2989.
   PubMed Web of Science ®Google Scholar
• Eshwar V, Kamath A, Shastry R, et al. A review of the safety of interleukin-17A inhibitor secukinumab. Pharmaceuticals. 2022;15:1365. doi: 10.3390/ph15111365
   Web of Science ®Google Scholar
• Wu CY, Chiu HY, Tsai TF. The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies. PLoS One. 2019;14:e0225112. doi: 10.1371/journal.pone.0225112
   PubMed Web of Science ®Google Scholar
• Loft ND, Vaengebjerg S, Halling AS, et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol. 2020;34:1151–1160. doi: 10.1111/jdv.16073
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, et al. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529–539. doi: 10.1111/1346-8138.14294
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Kamiya K, Okada H, et al. A case of acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis successfully treated with guselkumab. Int J Dermatol. 2023;62:269–270. doi: 10.1111/ijd.16153
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Okubo Y, Yasuda I, et al. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study. J Dermatol. 2023;50:195–202. doi: 10.1111/1346-8138.16667
   PubMedGoogle Scholar
• Hsieh CY, Tseng YH, Tsai TF. Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real-word evidence from a 52-week retrospective study. Exp Dermatol. 2023;32:2138–2148. doi: 10.1111/exd.14963
   PubMedGoogle Scholar
• Song EJ. Generalized pustular psoriasis treated with risankizumab. Cutis. 2023;111:96–98. doi: 10.12788/cutis.0695
   PubMed Web of Science ®Google Scholar
• Heyer S, Seiringer P, Eyerich S, et al. Acute generalized pustular psoriasis successfully treated with the IL-23p19 antibody risankizumab. J Dtsch Dermatol Ges. 2022;20:1362–1364. doi: 10.1111/ddg.14857
   Web of Science ®Google Scholar
• McFeely O, Pender E, Victory L, et al. Risankizumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol. 2022;47:616–617. doi: 10.1111/CED.15006
   PubMed Web of Science ®Google Scholar
• Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152:825–828. doi: 10.1001/jamadermatol.2016.0751
   PubMed Web of Science ®Google Scholar
• Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30:488–490. doi: 10.1111/jdv.12872
   PubMed Web of Science ®Google Scholar
• Ryan Andrulonis MD, Korb Ferris L. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11:1240.
   PubMed Web of Science ®Google Scholar
• Bonekamp N, Caorsi R, Viglizzo GM, et al. High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA). Ann Rheum Dis. 2018;77:1241–1243. doi: 10.1136/annrheumdis-2017-211805
   PubMed Web of Science ®Google Scholar
• Cherqaoui B, Rossi-Semerano L, Piram M, et al. Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist. Ann Rheum Dis. 2018;77:e88. doi: 10.1136/annrheumdis-2017-212793
   PubMed Web of Science ®Google Scholar
• Huang YW, Tsai TF. Pharmacological management of pediatric pustular psoriasis. Pediatr Drugs. 2020;22:265–277. doi: 10.1007/s40272-020-00383-6
   PubMed Web of Science ®Google Scholar
• Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy. Rheumatol Int. 2018;38:1297–1299. doi: 10.1007/s00296-018-4034-0
   PubMed Web of Science ®Google Scholar
• Wenk KS, Claros JM, Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatolog Treat. 2012;23:212–214. doi: 10.3109/09546634.2010.534430
   PubMed Web of Science ®Google Scholar
• Huang YW, Tsai TF. The seroconversion rate of QuantiFERON-TB gold in-tube test in psoriatic patients receiving anti-interleukin-23 monoclonal antibodies. Dermatol Sinica. 2022;40:94–99. doi: 10.4103/ds.ds_18_22
   Web of Science ®Google Scholar
• Bachelez H, Choon S-E, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–983. doi: 10.1056/nejmc1811317
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon S-E, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–2440. doi: 10.1056/nejmoa2111563
   PubMed Web of Science ®Google Scholar
• Elewski BE, Lebwohl MG, Anadkat MJ, et al. Rapid and sustained improvements in generalized pustular psoriasis physician global assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023;89:36–44. doi: 10.1016/j.jaad.2023.02.040
   PubMed Web of Science ®Google Scholar
• Burden AD, Okubo Y, Zheng M, et al. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the effisayil 1 study. Exp Dermatol. 2023;32:1279–1283. doi: 10.1111/exd.14824
   PubMed Web of Science ®Google Scholar
• Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11:e043666. doi: 10.1136/bmjopen-2020-043666
   PubMed Web of Science ®Google Scholar
• Hsieh CY, Huang YW, Huang YH, et al. Deficiency of interleukin-36 receptor antagonist (DITRA): an analysis of 58 Chinese patients in a tertiary hospital in Taiwan. Exp Dermatol. 2023;32:1272–1278. doi: 10.1111/exd.14783
   PubMed Web of Science ®Google Scholar
• Wang TS, Chiu HY, Hong JB, et al. Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients. Arch Dermatol Res. 2016;308:55–63. doi: 10.1007/s00403-015-1611-x
   PubMed Web of Science ®Google Scholar
• Choon SE, Tok PSK, Wong KW, et al. Clinical profile of patients with acute generalized pustular psoriasis with and without IL36RN mutations in multi-ethnic Johor Bahru, Malaysia. Exp Dermatol. 2023;32:1263–1271. doi: 10.1111/EXD.14776
   PubMed Web of Science ®Google Scholar
• Hsieh CH, Tsai TF. Treatment rescponses of four different biologics in a patient with recurrent generalized pustular psoriasis harboring IL36RN mutation. Dermatol Sin. 2023. doi: 10.4103/ds.DS-D-23-00107
   Google Scholar
• Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti-il-36 receptor monoclonal antibody for the treatment of generalised pustular psoriasis: results from the phase 2 GALLOP trial. Br J Dermatol. 2023;189:161–169. doi: 10.1093/bjd/ljad083
   PubMed Web of Science ®Google Scholar
• David Burden A, Okubo Y, Zheng M, et al. Effect of the presence or absence of genetic mutations on spesolimab efficacy in patients with generalized pustular psoriasis (GPP). 31st European Academy of Dermatology and Venereology (EADV) Congress:Milan Italy; 2022. n.d.
   Google Scholar
• Imsidolimab, top-line Phase 3 results from the GEMINI-1 trial. 2023 [cited 2023 Oct 11]. Available from: https://www.anaptysbio.com/pipeline/imsidolimab/
   Google Scholar
• Saeki H, Mabuchi T, Asahina A, et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50:e41–e68. doi: 10.1111/1346-8138.16691
   PubMed Web of Science ®Google Scholar
• Kamiya K, Ohtsuki M. Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020. J Dermatol. 2023;50:3–11. doi: 10.1111/1346-8138.16583
   PubMed Web of Science ®Google Scholar
• Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86:1266–1274. doi: 10.1016/j.jaad.2021.06.008
   PubMed Web of Science ®Google Scholar
• Abduelmula A, Rankin BD, Sood S, et al. Management of adult generalized pustular psoriasis using biologics: a systematic review. J Am Acad Dermatol. 2023;89:417–419. doi: 10.1016/J.JAAD.2023.04.031
   PubMed Web of Science ®Google Scholar
• Kodali N, Blanchard I, Kunamneni S, et al. Current management of generalized pustular psoriasis. Exp Dermatol. 2023;32:1204–1218. doi: 10.1111/exd.14765
   PubMed Web of Science ®Google Scholar
• Rivera-Díaz R, Daudén E, Carrascosa JM, et al. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther. 2023;13:673–688. doi: 10.1007/s13555-022-00881-0
   Web of Science ®Google Scholar
• Kromer C, Loewe E, Schaarschmidt ML, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34:e14814. doi: 10.1111/dth.14814
   PubMed Web of Science ®Google Scholar
• Iznardo H, Puig L, Narbutt J, et al. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci. 2021;22:4344. doi: 10.3390/IJMS22094344
   PubMed Web of Science ®Google Scholar
• Seishima M, Fujii K, Mizutani Y. Generalized pustular psoriasis in pregnancy: current and future treatments. Am J Clin Dermatol. 2022;23:661–671. doi: 10.1007/s40257-022-00698-9
   PubMed Web of Science ®Google Scholar
• Kawai Y, Tsuchiya T, Aoki S. Pregnancy outcomes of patients exposed to adalimumab in Japan. Dig Dis. 2019;37:123–130. doi: 10.1159/000493462
   PubMed Web of Science ®Google Scholar
• Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase®). BioDrugs. 2023;37:73–87. doi: 10.1007/s40259-022-00564-4
   PubMed Web of Science ®Google Scholar
• Narbutt J, Niedźwiedź M, Skibińska M, et al. Secukinumab for the treatment of psoriasis in pediatrics: patient selection and acceptability. Patient Prefer Adherence. 2023;17:421. doi: 10.2147/PPA.S350753
   PubMed Web of Science ®Google Scholar
• Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents. Pediatr Rheumatol Online J. 2019;17:17. doi: 10.1186/s12969-019-0338-1
   PubMed Web of Science ®Google Scholar